DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Teveten HCT (Eprosartan Mesylate / Hydrochlorothiazide) - Summary

 
 



USE IN PREGNANCY

When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, TEVETEN® HCT Tablets should be discontinued as soon as possible. See WARNINGS: Fetal/Neonatal Morbidity and Mortality.

 

TEVETEN HCT SUMMARY

TEVETEN® HCT 600/12.5 and TEVETEN® HCT 600/25 (eprosartan mesylate-hydrochlorothiazide) combine an angiotensin II receptor (AT1 subtype) antagonist and a diuretic, hydrochlorothiazide. TEVETEN® (eprosartan mesylate) is a non-biphenyl non-tetrazole angiotensin II receptor (AT1) antagonist.

TEVETEN® HCT is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensives such as calcium channel blockers. This fixed dose combination is not indicated for initial therapy (see DOSAGE AND ADMINISTRATION).


See all Teveten HCT indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Teveten HCT (Eprosartan / Hydrochlorothiazide)

Masked Hypertension Linked to Cognitive Decline
Source: theheart.org | Medscape Cardiology Headlines [2015.05.22]
Ambulatory blood-pressure measurements may reveal "the hidden risk" of diminished cognitive function in older patients, say researchers. In addition, this risk may be increased twofold, they report.
Heartwire from Medscape

New data show need for improved monitoring for pulmonary hypertension following pulmonary embolism
Source: Respiratory / Asthma News From Medical News Today [2015.05.20]
Results from a retrospective cohort study presented at the American Thoracic Society (ATS) 2015 International Conference in Denver found that the incidence of pulmonary hypertension (PH) among...

Managing Hypertension: Technology Challenges Old Habits
Source: MedPage Today Cardiovascular [2015.05.20]
(MedPage Today) -- More accurate automated readings should replace the standard of care in the U.S., says one advocate

American Society of Hypertension (ASH) 2015 Annual Scientific Meeting
Source: theheart.org | Medscape Cardiology Headlines [2015.05.18]
Read clinically focused news coverage of key developments from ASH 2015.
Medscape Cardiology

Odd genetic syndrome suggests increased blood vessel resistance could cause hypertension
Source: Hypertension News From Medical News Today [2015.05.13]
The culmination of two decades of research, a new study reveals the genetic causes of a curious, rare syndrome that manifests as hypertension (high blood pressure) accompanied by short fingers...

more news >>

Published Studies Related to Teveten HCT (Eprosartan / Hydrochlorothiazide)

Ambulatory monitoring of systolic hypertension in the elderly: Eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST trial). [2010.06]
INTRODUCTION: Systolic hypertension is very common in the elderly and is strongly associated with the risk of cardiovascular and cerebrovascular events. The control of systolic hypertension is difficult and most patients require combination antihypertensive therapy. Few data are available regarding the efficacy of angiotensin II receptor antagonists on systolic hypertension of the elderly. The aim of this double-blind, double-dummy, randomized, parallel-group, multicenter study was to assess the efficacy of eprosartan 600 mg in combination with hydrochlorothiazide (HCTZ) 12.5 mg in comparison with losartan 50 mg in combination with HCTZ 12.5 mg, in reducing blood pressure in elderly patients with grade 2 systolic hypertension who did not optimally respond to eprosartan or losartan monotherapy... CONCLUSION: In this study, eprosartan/HCTZ did not demonstrate to be superior to losartan/HCTZ in reducing ABPM systolic hypertension in the elderly.

Safety and tolerability of eprosartan in combination with hydrochlorothiazide. [2002]
The ideal antihypertensive drug should be effective in reducing blood pressure, but have a low incidence of adverse effects... Therefore, the combination of eprosartan with hydrochlorothiazide can be effectively and safely used in patients not adequately responding to eprosartan monotherapy.

more studies >>

Clinical Trials Related to Teveten HCT (Eprosartan / Hydrochlorothiazide)

Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension [Recruiting]
Aim of this study is to compare the blood pressure lowering effect of a new drug formulation of eprosartan. Eprosartan belongs to a class of blood pressure lowering agents used worldwide since years with proven efficacy. The new formulation is compared to the currently marketed eprosartan tablet. Equivalent efficacy in blood pressure lowering effects should be demonstrated.

The Effect of Eprosartan on Hormones and Kidney Function in Healthy Humans. [Completed]
We, the investigators at Holstebro Hospital, want to test the hypothesis that eprosartan

reduces the activity of the sympathetic nervous system in healthy individuals - during

baseline conditions and after activation of the sympathetic nervous system.

The Effect of Eprosartan on Hormones and Kidney Function in Patients With Essential Hypertension [Completed]
We, the investigators at Holstebro Hospital, want to test the hypothesis that eprosartan reduces the activity of the sympathetic nervous system in patients with essential

hypertension - during baseline conditions and after activation of the sympathetic nervous

system.

Comparison of Eprosartan/HCT Versus Enalapril/HCT in Hypertensives With Type II Diabetes [Completed]

Observational Study to Investigate the Effectiveness of Eprosartan on Pulse Pressure (Teveten_MS) [Recruiting]
The study is to identify the effectiveness of Eprosartan on pulse pressure in hypertensive patients with metabolic syndrome

- Definition of pulse pressure (PP): Difference between systolic and diastolic blood pressure

produced one heart beat.

more trials >>


Page last updated: 2015-05-22

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015